Yu M, Feng XY, Yao S, Wang C, Yang P. Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis. World J Clin Cases 2022; 10(26): 9524-9535 [PMID: 36159441 DOI: 10.12998/wjcc.v10.i26.9524]
Corresponding Author of This Article
Ping Yang, MD, PhD, Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, No. 126 Xiantai Street, Changchun 130031, Jilin Province, China. pyang@jlu.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2022; 10(26): 9524-9535 Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9524
Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis
Ming Yu, Xiao-Yu Feng, Shuai Yao, Chang Wang, Ping Yang
Ming Yu, Chang Wang, Ping Yang, Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, Changchun 130031, Jilin Province, China
Xiao-Yu Feng, Department of Endocrinology, Jilin Guowen Hospital, Changchun 130021, Jilin Province, China
Shuai Yao, Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun 130031, Jilin Province, China
Author contributions: Yu M and Feng XY conceived and designed the study; Yao S and Wang C collected and analyzed data; Yu M wrote the draft of the study; Yang P was responsible for the revision of the manuscript for important intellectual content; All authors issued final approval for the version to be submitted.
Supported byNational Natural Science Foundation of China, No. 81570360.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ping Yang, MD, PhD, Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, No. 126 Xiantai Street, Changchun 130031, Jilin Province, China. pyang@jlu.edu.cn
Received: April 15, 2022 Peer-review started: April 15, 2022 First decision: June 7, 2022 Revised: June 11, 2022 Accepted: August 9, 2022 Article in press: August 9, 2022 Published online: September 16, 2022 Processing time: 140 Days and 0.3 Hours
ARTICLE HIGHLIGHTS
Research background
Previous studies suggested that free fatty acid (FFA) concentration was potentially associated with anti-diabetic drugs of sulfonylurea (SU). The results were inconsistent. We assessed the effects of SU on the level of FFA concentration in diabetic patients.
Research motivation
SU is one of the most commonly used anti-diabetic medications. Several studies reported that SU treatment increased the risk of cardiovascular death and stroke in diabetic patients. Despite the reason for this result is unclear but may be related to the effect of SU on FFA and blood lipids.
Research objectives
The primary objective was to perform a meta-analysis of diabetic patients treated with SU and analyze changes in FFA concentration.
Research methods
We reviewed PubMed, EMBASE, Cochrane Library, Reference Citation Analysis (https://www.referencecitationanalysis.com/), and Web of Science databases to identify studies using SU for diabetic patients. The FFA value change was measured. A random-effect model or fixed-effect model was used according to the test of heterogeneity, and I2 index was used to assess the heterogeneity.
Research results
We included 13 observational studies comprising 16 treatment arms in the meta-analysis. FFA concentration was increased after the treatment of SU in diabetic patients. When combined with other antidiabetics, the effects of SU treatment on FFA concentration were more pronounced. There was no significant different effect of FFA concentration when treated with glimepiride or glibenclamide.
Research conclusions
Some SU drugs increased serum FFA concentration in diabetic patients.
Research perspectives
The association between FFA concentration and SU treatment requires more studies and longer follow-up.
